Wall Street analyst estimates for Nyxoah S.A. (NYXH): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.37 | ||
| 2026-08-05 | $-0.67 | $-0.47 | -42.6% |
| 2026-05-12 | $-0.43 | $-0.54 | +20.4% |
| 2026-03-19 | $-0.68 | $-0.65 | -4.6% |
| 2025-11-13 | $-0.74 | $-0.61 | -21.3% |
| 2025-08-18 | $-0.63 | $-0.62 | -1.6% |
| 2025-05-14 | $-0.63 | $-0.49 | -28.6% |
| 2025-03-13 | $-0.49 | $-0.46 | -6.5% |
Valuation Ratios
| Price / Book | 0.88 |
| EV / EBITDA | -1.59 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $69000 | $852000 | $3.1M | $4.3M | $4.5M | $10.0M |
| Cost of Revenue | $89255 | $95078 | $486042 | $30000 | $303000 | $1.1M | $1.7M | $1.6M | $3.7M |
| Gross Profit | -$89255 | -$95078 | -$486042 | $39000 | $549000 | $1.9M | $2.7M | $3.0M | $6.3M |
| Research & Development | $1.5M | $1.4M | $1.6M | $2.9M | $6.0M | $15.9M | $27.7M | $34.3M | $42.8M |
| Selling, General & Admin | $4.1M | $7.5M | $4.5M | $11.3M | $11.1M | $18.9M | $20.6M | $28.5M | $46.4M |
| Operating Expenses | $8.8M | $8.9M | $8.0M | $11.3M | $26.8M | $34.4M | $47.8M | $61.8M | $89.3M |
| Operating Income | -$10.1M | -$8.4M | -$8.5M | -$11.2M | -$26.2M | -$32.5M | -$45.1M | -$58.8M | -$82.9M |
| EBITDA | -$8.7M | -$8.5M | -$8.2M | -$10.6M | -$22.6M | -$27.9M | -$42.1M | -$53.8M | -$82.9M |
| Interest Expense | $37000 | $29000 | $701562 | $198000 | $386000 | $237000 | $1.2M | $1.9M | $1.7M |
| Pre-tax Income | -$10.3M | -$9.0M | -$9.4M | -$12.2M | -$24.6M | -$30.1M | -$44.7M | -$56.4M | -$89.1M |
| Income Tax | $37000 | $41000 | $78574 | $93000 | $3.0M | $1.2M | -$1.4M | $2.8M | $1.0M |
| Net Income | -$10.4M | -$9.1M | -$8.5M | -$12.2M | -$27.6M | -$31.2M | -$43.2M | -$59.2M | -$90.1M |
| EPS | $-0.50 | $-0.43 | $-0.39 | $-0.68 | $-1.16 | $-1.21 | $-1.55 | $-1.81 | $-2.36 |
| EPS (Diluted) | $-0.50 | $-0.43 | $-0.39 | $-0.68 | $-1.16 | $-1.21 | $-1.55 | $-1.81 | $-2.36 |
| Shares Outstanding (Diluted) | $20.9M | $20.9M | $21.4M | $18.1M | $23.8M | $25.8M | $28.0M | $32.7M | $38.1M |
Price
| Price | $1.49 |
| Market Cap | $149M |
| Exchange | NASDAQ |
| Country | BE |
Related companies: CATX · GNFT · IVVD · KRMD · OABI · OSUR · PRE
Explore sector: Healthcare · Medical - Specialties
More sections of NYXH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks